Български
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Страница 1 от 18 резултата
Methods of screening for agonists and antagonists of the interaction between the human KIAA0001 receptor and ligands thereof
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
FIELD OF THE INVENTION
This invention relates to methods for discovering agonists and antagonists of the interaction between UDP-sugars (e.g.,UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine) and their cellular receptor, human KIAA0001 receptor. The invention also
Benzimidazolone derivatives as CB2 receptor ligands
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
This invention relates to benzimidazolone derivatives. These compounds have selective cannabinoid(CB)2 receptor binding activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the
Sulfonyl benzimidazole derivatives
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
This invention relates to sulfonyl benzimidazole derivatives. These compounds have selective cannabinoid (CB)2 receptor agonistic activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives
Human G-protein coupled receptor
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor
Antibodies immunospecific for a novel human G-protein coupled receptor family
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to a G-protein coupled receptor
Morpholine and thiomorpholine tachykinin receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
Analgesia has historically been achieved in the central nervous system by opiates and analogs which are addictive, and peripherally by cyclooxygenase inhibitors that have gastric side effects. Substance P antagonists may induce analgesia both centrally and peripherally.
Morpholine and thiomorpholine tachykinin receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
Analgesia has historically been achieved in the central nervous system by opiates and analogs which are addictive, and peripherally by cyclooxygenase inhibitors that have gastric side effects. Substance P antagonists may induce analgesia both centrally and peripherally.
Morpholine and thiomorpholine tachykinin receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
Analgesia has historically been achieved in the central nervous system by opiates and analogs which are addictive, and peripherally by cyclooxygenase inhibitors that have gastric side effects. Substance P antagonists may induce analgesia both centrally and peripherally.
Morpholine and thiomorpholine tachykinin receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
Analgesia has historically been achieved in the central nervous system by opiates and analogs which are addictive, and peripherally by cyclooxygenase inhibitors that have gastric side effects. Substance P antagonists may induce analgesia both centrally and peripherally.
Morpholine and thiomorpholine tachykinin receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
Analgesia has historically been achieved in the central nervous system by opiates and analogs which are addictive, and peripherally by cyclooxygenase inhibitors that have gastric side effects. Substance P antagonists may induce analgesia both centrally and peripherally.
Morpholine and thiomorpholine tachykinin receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
Analgesia has historically been achieved in the central nervous system by opiates and analogs which are addictive, and peripherally by cyclooxygenase inhibitors that have gastric side effects. Substance P antagonists may induce analgesia both centrally and peripherally.
Process for preparing morpholine tachykinin receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
SUMMARY OF THE INVENTION
This invention is concerned with novel compounds represented by structural formula I: ##STR2##
wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and X are hereinafter defined.
The invention is also concerned with pharmaceutical formulations comprising these novel
Aminoadamantane derivatives as therapeutic agents
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Най-пълната база данни за лечебни билки, подкрепена от науката
- Работи на 55 езика
- Билкови лекове, подкрепени от науката
- Разпознаване на билки по изображение
- Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
- Прочетете научни публикации, свързани с вашето търсене
- Търсете лечебни билки по техните ефекти
- Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите
Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания
